Kura Oncology (KURA) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Kura Oncology (KURA) has outperformed Wave Life Sciences (WVE) over the past year, losing 7.7% versus a loss of 59.9%. Over five years, WVE leads with a -27.9% price change compared with -48.3% for KURA. Kura Oncology is the larger company by market cap ($807.8 million vs $616.8 million), about 1.3 times the size.
Kura Oncology converts more of its revenue into profit, with a net margin of -412.9% versus -478.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KURA | WVE |
|---|---|---|
| Share price | $9.08 | $3.13 |
| Market cap | $807.76M | $616.76M |
| 1-day change | -6.39% | -1.88% |
| YTD return | -12.61% | -81.59% |
| 1-year return | -7.72% | -59.92% |
| 5-year return | -48.29% | -27.88% |
| EPS (TTM) | $-3.37 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.48M | $42.73M |
| Revenue growth (YoY) | +25.24% | -60.55% |
| Net income (latest FY) | $-278.67M | $-204.38M |
| Operating margin | -449.94% | -504.09% |
| Net margin | -412.95% | -478.33% |
| 52-week high | $13.90 | $21.73 |
| 52-week low | $7.36 | $3.04 |
| Distance from 52-week high | -34.68% | -85.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +250.77% | +450.16% |
| Average volume | 1.82M | 3.17M |
| Shares outstanding | 88.96M | 197.05M |
| Employees | 260 | 317 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KURA has outperformed WVE by 52.2 percentage points over the past year.
- Kura Oncology is more profitable, keeping -412.9 cents of every revenue dollar as net income versus -478.3 cents for Wave Life Sciences.
- Kura Oncology grew revenue faster in its latest fiscal year (+25.24% vs -60.55%).
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Healthcare · Biotechnology · 260 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Healthcare · Biotechnology · 317 employees
KURA vs WVE FAQ
Which is bigger, Kura Oncology or Wave Life Sciences?
Kura Oncology (KURA) is larger, with a market capitalization of $807.76M compared with $616.76M for Wave Life Sciences (WVE).
Which stock has performed better over the past year, KURA or WVE?
KURA returned -7.72% over the past 12 months, compared with -59.92% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Kura Oncology and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.